^
Association details:
| Biomarker: | PALB2 mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Olaparib In Metastatic Breast Cancer
Excerpt:
...- Cohort 1a: germline PALB2 mutation -- The mutation must be identified through a CLIA-approved NGS panel....
Trial ID:
Source:
Title:
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.
Excerpt:
...Capacity of the RAD51-foci score to predict the efficacy of olaparib in BRCA1/2, PALB2 or RAD51C/D mut advanced breast cancer (cohort 1)...
Trial ID:
More C2 evidence
Source:
Title:
Predicting olaparib sensitivity in metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutation or RAD51-negative test Predicción de la sensibilidad a Olaparib en pacientes con cáncer de mama HER2 negativo localmente avanzado irresecable o metastásico con mutaciones en BRCA1, BRCA2, PALB2, RAD51C o RAD51D o con niveles bajos RAD51
Excerpt:
...Los pacientes deben ser hombres o mujeres de ≥18 años 3.Los pacientes deben de tener la capacidad de proporcionar un formulario de consentimiento informado por escrito firmado y fechado antes de cualquier procedimiento, muestreo y análisis.4.Cáncer de mama confirmado histológica o citológicamente con evidencia de enfermedad localmente avanzada5.Los pacientes pueden tener cáncer de mama triple negativo y HER2 negativo o cáncer de mama ER / PgR positivo, siempre que sean HER2 negativo y coherentes con los estándares locales y las pautas más recientes de ASCO CAP Cohorte 1: Mutación en BRCA1, BRCA2, PALB2, RAD51C o RAD51D 6.Pacientes que hayan recibido platino y no haya habido evidencia de progresión de la enfermedad durante la quimioterapia.7.Pacientes que hayan recibido platino y / o inhibidores de PARP y que hayan transcurrido al menos 6 meses entre la última dosis de PARP. ...
Trial ID:
Less C2 evidence
Source:
Title:
88P - Efficacy of olaparib in advanced cancers occurring in patients with germline or somatic tumor mutations in homologous recombination (HR) genes, a Belgian Precision phase II basket study
Published date:
09/13/2021
Excerpt:
One complete response was observed in a stage IV breast cancer that harbours a PALB2 germline mutation....Treatment with olaparib shows activity in cancer pts with a HR gene mutation and is well tolerated.
Source:
Title:
TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).
Published date:
05/13/2020
Excerpt:
Patients received olaparib 300 mg...Responses were gene specific (Table): gPALB2 and sBRCA mutations predicted response…
DOI:
10.1200/JCO.2020.38.15_suppl.1002
Trial ID:
Source:
Title:
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Excerpt:
Patients received olaparib 300 mg orally twice a day until progression….In cohort 1, ORR was 33% (90% CI, 19% to 51%) and in cohort 2, 31% (90% CI, 15% to 49%). Confirmed responses were seen only with gPALB2 (ORR, 82%) and sBRCA1/2 (ORR, 50%) mutations....PARP inhibition is an effective treatment for patients with MBC and gPALB2 or sBRCA1/2 mutations, significantly expanding the population of patients with breast cancer likely to benefit from PARPi beyond gBRCA1/2 mutation carriers.
DOI:
10.1200/JCO.20.02151
Trial ID:
